ORAI3 and prostate cancer: They found that prostate cancer cells can undergo an “oncogenic switch.” The increase in Orai3 expression and alterations of tumor microenvironment leads to an increased heteromerization of Orai1 and Orai3, which contributes to the phenotypic transition from SOCE, which is pro-apoptotic, to an Orai1/Orai3 channel that is pro-proliferative.